Chu Christopher H, Davis Charles
School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC, 29209, USA.
Dorn VA Medical Center, Columbia, SC, USA.
Drug Saf Case Rep. 2017 Dec;4(1):9. doi: 10.1007/s40800-017-0051-2.
A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated. She was diagnosed with urticaria, and ustekinumab was discontinued. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab. Ustekinumab was subsequently discontinued, and the patient received a course of Harvoni (Gilead Sciences, Inc., Forest City, California, United States) (ledispasvir/sofosbuvir) with clearance of the hepatitis C virus. The patient is currently receiving another biologic agent, ixekizumab, and reports no complaints, including that of urticaria.
一名62岁有丙型肝炎和2型糖尿病病史的白人女性在使用乌司奴单抗治疗斑块状银屑病期间出现了荨麻疹。该患者在最初2个月内接受了两次45毫克的乌司奴单抗注射，之后每3个月注射一次45毫克用于治疗银屑病。10个月后，她全身皮肤出现弥漫性圆形红色皮疹。她还抱怨手部关节疼痛。风湿病科介入，检查发现她的抗核抗体滴度为阴性，但类风湿因子、红细胞沉降率和肝功能酶升高。她被诊断为荨麻疹，乌司奴单抗停药。Naranjo评估评分为6分，表明患者的荨麻疹与使用乌司奴单抗之间可能存在关联。随后停用了乌司奴单抗，患者接受了一个疗程的Harvoni（吉利德科学公司，美国加利福尼亚州森林城）（来迪派韦/索磷布韦），丙型肝炎病毒清除。患者目前正在接受另一种生物制剂司库奇尤单抗治疗，且未报告任何不适，包括荨麻疹。
